

State Reform of Medicaid Drug Programs

Policy Backgrounder No. 165

by Devon Herrick

April 2012

Medicaid is a joint federal-state program that provides medical care to more than 60 million low-income individuals and families.¹ Medicaid rolls in many states have risen over the past several years as a result of the recession and continuing high unemployment. Indeed, in 2011 the average growth rate in Medicaid spending was about 6.1 percent.²



Dallas Headquarters:
12770 Coit Road, Suite 800
Dallas, TX 75251-1339
972.386.6272

www.ncpa.org

Washington Office:
601 Pennsylvania Avenue NW,
Suite 900, South Building
Washington, DC 20004
202.220.3082



The program is the largest single expenditure by state governments today, accounting for one-in-every-five dollars of state spending. Medicaid is currently on course to consume the entire budgets of some state governments in just a few decades.^{3,4}

Restraining the growth of Medicaid spending is a fiscal imperative for state budgets. States should start by looking for ways to control spending in their drug benefit programs. Billions of dollars in potential savings could be realized without reducing access to needed care for any Medicaid enrollees.

Broader use of prescription drugs for chronic illness can reduce Medicaid costs by avoiding expensive emergency room visits, costly complications and surgeries. Examples include drugs to treat asthma, diabetes and heart disease. State Medicaid programs that fail to realize the full benefits of drug therapy could end up paying more for more costly hospital treatments. This problem is particularly acute due to the expected increase in Medicaid enrollment as a result of the Patient Protection and Affordable Care Act (ACA).

The ACA will significantly expand Medicaid eligibility to individuals with incomes from 100 percent to 133 percent of the federal poverty level. Over the next few years, Medicaid and Children's Health Insurance Program (CHIP) enrollment is expected to swell to nearly 84 million people.⁵ The Congressional Budget Office estimates the new law will add 16 million Medicaid enrollees.⁶ Other estimates place the number of additional enrollees closer to 20 million.⁷

Initially, the federal government will pay 100 percent of the cost for the newly eligible who enroll, and 95 percent of costs through 2019. However, new enrollees who were previously eligible for Medicaid must be paid for under each state's current federal matching formula.⁸ When the individual mandate requiring all legal U.S. residents to obtain health coverage takes effect in 2014, 10 million or more previously eligible uninsured are likely to be enrolled in Medicaid through outreach efforts.⁹ As a result, state Medicaid spending will soar.¹⁰

Medicaid Spending on Drug Therapy

Americans see their doctors more than 890 million times each year, and two-thirds of office visits to physicians result in prescription drug therapy.¹¹ Indeed, drug expenditures are one of the fastest growing components of the Medicaid program.

Numerous studies by Columbia University professor Frank Lichtenberg have found that increased spending on newer, patented drug therapies is often offset by reduced spending on inpatient care.¹² Drug treatment for schizophrenia, for example, can help avoid costly hospitalizations. A variety of drugs

exist to treat this condition, but some are more effective and better tolerated by some patients than by others. Thus, individual state laws that make it difficult for schizophrenia patients to obtain the appropriate medication result in more expensive inpatient treatment.

The Role of Private Drug Plans in Reducing Medicaid Drug Costs. The way state Medicaid drug programs work depends on whether drug benefits are managed by a private health plan, run by state officials or administered by a pharmacy benefit manager (PBM) — a private firm that contracts with a state. Regardless of the program's structure, Medicaid enrollees still usually purchase their drugs at local

pharmacies that are reimbursed for the cost of each prescription filled, plus a dispensing fee.


States that manage their own drug benefits may negotiate drug discounts and also receive federally-required drug rebates. The prices states pay for drugs often differ from one state to the next; sometimes from one pharmacy to the next. In private plans, pharmacy benefit managers typically negotiate drug dispensing fees with pharmacies. Rather than using these negotiated fees, however, states often arbitrarily pay pharmacies much more. For instance, most conventional Medicaid programs pay higher dispensing fees than privately run

Medicare Part D drug plans. Virtually all state Medicaid programs manage some of their drug distribution, and half the states distribute all of their Medicaid drugs this way. Overall, nearly three-fourths (73 percent) of Medicaid drug spending is reimbursed and administered separately from a health plan.

Many states “carve out” pharmacy benefits and administer them separately from health plans on a fee-for-service basis. This is the way conventional state Medicaid drug benefits are administered for enrollees not in managed care. [See Figure I.]

Private health

Figure I
Percent of Medicaid Drugs on a Fee-for-Service Basis



Source: Joel Menges, Shirley Kang and Chris Park, “Potential Federal and State-by-State Savings if Medicaid Pharmacy Programs Were Optimally Managed,” Lewin Group, February 2011.

plans use a variety of techniques to control drug costs, including preferred drug lists, formularies, required use of mail-order drug suppliers, and negotiated prices with drug companies and distributors.¹³ Health plans frequently contract with pharmacy benefit managers to promote the use of cost-effective drugs within specific classes to reduce costs.

Because they operate in a competitive environment, private drug plans tend to administer drug benefits more efficiently than state Medicaid programs. They can negotiate agreements for drug reimbursements and dispensing fees that are less lucrative to providers than state-run Medicaid programs, which are susceptible to the political influence of lobbyists and special interests.

Special interests lobby legislatures to restrict the ability of pharmacy benefit managers to negotiate better deals. Their efforts have been intense. Indeed, when the Lewin Group, a consulting firm, released reports highlighting methods to improve Medicaid drug program efficiency, trade associations at risk of losing income responded swiftly.¹⁴ Representatives for community pharmacists argued that patients could be harmed, alleging Lewin’s results were “bought and paid for” by drug plans.¹⁵

How Federal Policy Discourages Integrating Drug Benefits with Health Benefits.

The federal government requires drug manufacturers to rebate to state Medicaid programs at least 23.1 percent of the average manufacturer’s (wholesale) price

for brand drugs and 13 percent for generic drugs. States often negotiate additional rebates, and total Medicaid rebates average nearly 40 percent.¹⁶ Prior to the ACA, the rebates were available for state-administered drug programs, but not to privately operated drug plans. Thus, in order to receive the rebates, many states chose to carve out drug benefits and administer them separately from private contractors’ integrated health plans.¹⁷ Lately, states have begun to “carve in” (that is, integrate) Medicaid drug benefits with enrollees’ health benefits and place more Medicaid enrollees in managed care plans.

“States that administer their own Medicaid drug benefits could save money by using private contractors.”


How State Policies Preclude Efficient Drug Programs. A variety of state laws hamper negotiations between Medicaid drug plans, drug makers and pharmacies. Two of these are “any willing provider” and “freedom of choice” laws. Nearly half the states have any willing provider laws that require insurers, health maintenance organizations and drug plans to allow into their provider network any pharmacy that accepts the terms of their provider contract.¹⁸ Similarly, freedom of choice laws allow enrollees to fill a prescription at almost any pharmacy willing to abide by the terms of the networks’ contracts. In general, enrollees cannot be

required to fill prescriptions only at selected pharmacies and often cannot be required to use the drug plans’ mail-order pharmacy. This is the case in Texas and other states. Recent changes to the Texas Medicaid drug program prevent drug plans from requiring enrollees to use more efficient mail-order pharmacies. Regulations also deter selective contracting with some pharmacies while excluding others. In addition, drug plans must adhere to the Vendor Drug Program (which processes out-patient pharmacy prescriptions for Medicaid, CHIP and other public health programs in Texas) and the state drug list.¹⁹

Consumer protection laws are costly to taxpayers; when drug plans create pharmacy networks they negotiate with pharmacies for the best prices. This ultimately holds down state Medicaid drug plan expenditures. The negotiated prices are the result of bargaining power — the ability of the drug plan to deny business to a firm. However, any willing provider and freedom of choice laws interfere with that negotiating process by reducing the drug plans’ bargaining power.²⁰

Proponents of unrestricted drug plans argue they offer enrollees a larger network of providers, with more choice and competition. Opponents counter that these laws prevent selective contracting, whereby a pharmacy chain agrees to deeper discounts in return for steering a greater volume of business to them by making them the exclusive in-network drug vendor. The evidence is that any willing provider laws increase drug expenditures by preventing the sort

Figure II
Use of Generic Drugs in Fee-for-Service Medicaid
(percent of prescriptions)



Source: Joel Menges, Shirley Kang and Chris Park, "Potential Federal and State-by-State Savings if Medicaid Pharmacy Programs Were Optimally Managed," Lewin Group, February 2011.

of negotiation that accompanies the ability to selectively contract.²¹ These laws also boost the administrative burden by about 43 percent, by increasing the number of pharmacy claims that must be adjudicated and paid.²²

Laws limiting the ability of drug plans to sign exclusive agreements in return for lower prices protect less-efficient pharmacies from competition. The Federal Trade Commission notes that these laws reduce bargaining power, which leads to higher drug prices and higher premiums.²³ Thus, any willing provider and freedom of

choice typically benefit pharmacies rather than consumers.²⁴

Some states also specifically limit copayments and prohibit different copayment amounts among pharmacies, keeping managed care organizations and pharmacy benefit management companies from steering Medicaid enrollees to preferred pharmacies. This policy reduces competition by artificially standardizing copayments.

State Drug Lists as a Barrier to Reform. Many states carve out portions of their pharmacy program to retain state control

of pharmacy benefits for special beneficiary groups and classes of drugs. For instance, some states use state-specific prescription drug lists, rather than preferred drug lists negotiated and developed by pharmacy benefit managers. One survey comparing drug lists from state-run Medicaid programs to the World Health Organization's "Essential Medicines" list found the drugs automatically covered were arbitrary and varied from state to state.²⁵ State-sponsored drug lists give special interests and lobbying organizations the opportunity to influence state Medicaid

formularies, increasing costs to taxpayers and reducing competition among drug makers vying to be on the preferred drug list. One example is New York state, where “prescriber prevails” regulations limit the ability of drug plans to steer enrollees to more cost-effective drugs, such as generic versions of name-brand drugs.²⁶

State drug lists can also adversely impact patient care when they are poorly designed. Indeed, Medicaid programs run the risk of creating lists that boost utilization of other, more costly medical services — such as inpatient services.²⁷ Pharmaceutical trade associations caution that expensive physician (and inpatient) care often substitutes for less expensive drug therapies.²⁸ There is evidence that some states do not consistently establish preferred drug lists that satisfy patients’ needs.²⁹ Poorly designed drug lists discourage the use of beneficial medications or encourage the use of medications that are less safe and effective.³⁰

Potential Savings from Integrating Drug Benefits and Coordinating Care. State Medicaid programs that carve out drug benefits often do not pay sufficient attention to coordination and management of drug therapies. This responsibility is essentially taken away from health plans and taken over by the state. This can lead to drug policies that harm patients.³¹ For instance, the state of New Hampshire implemented an arbitrary prescription limit on psychiatric drugs in 1990 that led to an increase in the use of emergency mental

health services and hospitalizations for people with schizophrenia. The additional medical costs associated with poor medication management was 17 times the savings from limiting prescriptions.³² The Lewin Group has found that drug benefit programs that are integrated with privately-run health plans are more cost-effective than when they are administered separately.³³ Indeed, a Lewin analysis found that integrating Medicaid health plan and drug benefits in 14 states that

“Combining drug and medical plans could save Medicaid billions of dollars.”

currently exclude drug coverage from Medicaid private health plans would collectively save nearly \$12 billion over a decade.³⁴

Cost-Saving Strategies

The Lewin Group estimates that state and federal governments could save \$32.7 billion over 10 years by improving the efficiency of their Medicaid drug programs without detriment to enrollees’ health.³⁵

There are several effective strategies that states can use to better manage and lower Medicaid drug costs. Two of the most important are encouraging generic drug use when appropriate and paying competitive market rates for drug dispensing.

Encouraging Generic Drug Use Where Appropriate. There are numerous drug therapies to treat most conditions, some of which cost more than others. Patients can lower drug expenditures by taking available generic versions of medications. For instance:

- The U.S. health care system saved \$824 billion over the past decade from the use of generic drugs, according to one estimate.³⁶
- For retail customers, generic drug prices are generally 20 percent to 80 percent lower than the original branded drug.³⁷

Only those medications whose patent has expired are available in generic form, however. Some well-known drugs that have recently lost patent protection include Prozac and Zoloft (for depression), Claritin, Allegra and Zyrtec (for allergy relief), Zocor (to lower blood cholesterol), and Prevacid and Prilosec (for ulcers and gastric reflux disease). The number of generic equivalents available will increase over the next few years as many so-called blockbuster drugs lose patent protection and face generic competition. Indeed, many of the current top-selling name brand drugs will lose patent protection by the end of 2014.³⁸

Today about 78 percent of the prescriptions Americans fill are generic drugs.³⁹ This compares to about 19 percent in 1985.⁴⁰ Two-thirds of the drugs dispensed by the Veterans Affairs (VA) health system are generic, but they represent only 8 percent of the VA’s prescription costs.⁴¹ Though generic drugs are widely prescribed, there are potential

State Reform of Medicaid Drug Programs

savings from even wider use:⁴²

- Generic drugs make up 64 percent of all Medicaid prescriptions, but less than one-fifth (18 percent) of Medicaid drug spending.
- The average cost of a generic drug prescription in the Medicaid program is \$20, compared to the \$201 average for name-brand medications (including drugs for which there are no generic equivalents).

States can save money by encouraging generic drug utilization when appropriate. Indeed, most patients should consider a generic

drug with the understanding they can switch to a newer (brand) drug under patent protection if they have an adverse reaction or do not respond well to the generic.


A 100 percent generic fill-rate is not the ideal way to save money or ensure quality. The appropriate use of generic drugs — including those circumstances when a newer, patented drug is more suitable — will vary from patient to patient and from drug to drug. Lichtenberg has repeatedly argued that reduced mortality is associated with the introduction of innovative (patented) drugs.⁴³ In creating preferred drug

lists, the health of the patient should be the primary concern. There should also be protocols for those situations when a physician believes a patented drug is more appropriate.

Across all 50 states, the average proportion of prescriptions filled with a generic drug in conventional state-managed Medicaid drug programs is just over two-thirds (68 percent), compared to 80 percent for drug programs that are run by Medicaid health plans.⁴⁴

- The lowest users of generic drugs are Tennessee (47 percent), Maryland (62 percent), New York

Figure III
State Prescription Dispensing Fees



Note: Arizona has a small fee-for-service program; Medicare Part D for comparison purposes only.

Source: "Medicaid Prescription Reimbursement Information by State – Quarter Ending December 2011," Centers for Medicare and Medicaid Services, U.S. Department of Health and Human Services, February 2012. Available at: <http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Downloads/4QStatePrescriptionDrugRes.pdf>.

(63 percent) and New Jersey (63 percent).

- The highest users of generic drugs are Hawaii (79 percent), Massachusetts (77 percent) and Washington (76 percent). [See Figure II.]

All states should encourage the use of less-expensive drug alternatives when the therapeutic effectiveness is the same.⁴⁵ This change could result in substantial savings.

One report identified 20 commonly-used brand drugs for which there were therapeutically equivalent generic drugs available. Had state Medicaid programs substituted generics for these 20 drugs, the savings would have amounted to \$329 million in 2009, or about 22 percent more than if generic drugs had been fully utilized. Of the 20 drugs studied, Medicaid paid an average of \$95 more for every brand medication sold when there was a generic available.⁴⁶

Negotiating Dispensing Fees.

Consumers who are not in a drug plan do not pay a separate dispensing fee when purchasing drugs. The cost of dispensing a drug — counting tablets, filling bottles and administrative tasks — are included in the retail cost. The \$4 price for selected 30-day generic prescriptions at Wal-Mart, Target, Kroger and other pharmacies, for example, includes an implicit dispensing fee. Private drug plans typically negotiate dispensing fees with a pharmacy network or chain. By contrast, dispensing fees in state-managed, conventional Medicaid plans are set by state officials with

guidance from the state legislatures. Many states also have a statutory dispensing fee rather than allowing pharmacy benefit management companies to negotiate fees, as is common among Medicare Part D plans. As a result, pharmacy benefit management companies cannot negotiate dispensing fees with pharmacies based on the competitive environment.

State reimbursement rates to pharmacies filling Medicaid prescriptions vary more than is warranted by market conditions and business costs. State officials and state legislatures often yield to political pressure and set dispensing fees for conventional Medicaid programs that are not what the market would. If fees are too low, the revenue from filling Medicaid prescriptions is less than the cost of providing the service. As a result, enrollees may lack access to pharmacies willing to dispense drugs for Medicaid patients. On the other hand, if the fees are set too high, taxpayers end up paying pharmacies more than a competitive market. Politicians often protect local constituents — including local pharmacies — from competition for Medicaid’s business.⁴⁷

Lobbyists for pharmacies are keen to take advantage of this tendency. For instance, when the Texas Legislature began to debate reforming its Medicaid drug program, the Pharmacy Choice and Access Now Coalition opposed moving Medicaid drug reimbursements from the Vendor Drug Program to managed care. This move would not only reduce state Medicaid administrative costs, but could lower reimbursements to pharmacies as well. Under the old

reimbursement model, pharmacies that filled a Medicaid prescription were paid approximately \$7.50 plus a separate cost for the drug. By contrast, a pharmacy benefit management company contracting with a managed care plan may have negotiated a dispensing fee that is only one-third that price. Indeed, the

“The drug dispensing fee is \$1.75 in New Hampshire and \$10.64 in Alabama.”

Texas Pharmacy Business Council, which represents pharmacies, complained that in some cases privately-run pharmacy benefit management companies could drive down Medicaid dispensing fees as much as 80 percent if they were allowed to negotiate them down to market rates. The Choice and Access Now Coalition also opposed similar moves in Illinois and California.⁴⁸ What many of the special interest groups fail to disclose, however, is that the reimbursements and dispensing fees are not being cut due to legislation, but due to negotiated contracts in a free market.

- Across the country, the average Medicaid dispensing fee is \$4.81 per prescription.⁴⁹
- However, fees range from \$1.75 in New Hampshire to \$10.64 in Alabama.⁵⁰ [See Figure III and the table.]
- Under certain conditions, the dispensing fees climb even higher

State Reform of Medicaid Drug Programs

State Prescription Dispensing Fees

	Fee or Lower Tier	Upper Tier	
Alabama	\$10.64		
Alaska	\$3.45	\$11.46	**
Arizona	\$2.00		
Arkansas	\$5.51		
California	\$7.25	\$8.00	+
Colorado	\$4.00	\$1.89	+
Connecticut	\$3.15		
Delaware	\$3.65		
District of Columbia	\$4.50		
Florida	\$3.73	\$7.50	
Georgia	\$4.33	\$4.63	
Hawaii	\$4.67		
Idaho	\$4.94		
Illinois	\$3.40	\$4.60	*
Indiana	\$4.90		
Iowa	\$4.34		
Kansas	\$3.40		
Kentucky	\$4.50	\$5.00	*
Louisiana	\$5.77		
Maine	\$3.35		
Maryland	\$2.67	\$3.69	*
Massachusetts	\$3.00		
Michigan	\$2.50	\$2.75	+
Minnesota	\$3.65		
Mississippi	\$3.91	\$5.50	*
Missouri	\$4.09		
Montana	\$5.04		
Nebraska	\$3.27	\$5.00	
Nevada	\$4.76		
New Hampshire	\$1.75		
New Jersey	\$3.73	\$3.99	
New Mexico	\$2.50	\$3.65	
New York	\$3.50	\$4.50	*
North Carolina	\$4.00	\$5.60	*
North Dakota	\$4.60	\$5.60	*
Ohio	\$3.70		
Oklahoma	\$4.02		
Oregon	\$9.68	\$14.01	**
Pennsylvania	\$4.00		
Rhode Island	\$3.40		
South Carolina	\$4.05		
South Dakota	\$4.75		
Tennessee	\$2.50	\$3.00	*
Texas	\$7.50	Plus 2%	
Utah	\$3.90	\$4.40	++
Vermont	\$4.75		
Virginia	\$3.75		
Washington	\$4.24	\$5.25	
West Virginia	\$2.50	\$5.30	*
Wisconsin	\$3.44	\$3.94	*
Wyoming	\$5.00		
Average	\$4.23	\$5.42	

* generic drugs; ** higher fee for low-volume pharmacies; + institutional pharmacy; ++ higher fees for rural pharmacies

Source: “Medicaid Prescription Reimbursement Information by State – Quarter Ending December 2011” Centers for Medicare and Medicaid Services, U.S. Department of Health and Human Services, February 2012. Available at: <http://www.medicare.gov/Medicare-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Downloads/4QStatePrescriptionDrugRes.pdf>.

— in some cases as high as \$12.50, about double the market rate pharmacy benefit managers pay pharmacies for prescriptions covered by private drugs plans.⁵¹

- By contrast, the privately-managed Medicare Part D plans pay pharmacies a fee of about \$2 for every prescription they fill, or about \$1.90 for a short-term supply of pills and \$2.20 for an extended supply of drugs.⁵²

The appropriate dispensing fee varies from region to region. As a result, state officials need to allow pharmacy benefit managers for Medicaid to negotiate dispensing fees with pharmacy networks the way they do for private drug plans. This does not mean fees would be the same in every state or every pharmacy. However, it does mean dispensing fees would reflect local market conditions, such as the cost of doing business and competition.

Other Cost-Saving Strategies. Other cost-savings strategies include coordinating and tracking drug therapies, establishing reimbursement rates for drug makers similar to what commercial drug plans pay, and empowering patients with control of some of the dollars spent on their drug therapies so that they become better consumers.

Coordinating and Tracking Drug Therapy Utilization. Many states do not optimally manage their Medicaid drug programs.⁵³ For instance, conventional Medicaid programs do little to track the number of providers a Medicaid enrollee sees or the number of prescription drugs an enrollee has filled. Not tracking drug utilization makes conventional Medicaid programs susceptible to waste and fraud.

While some states manage their own Medicaid drug programs or contract directly with pharmacy benefit managers, others rely on insurers to manage benefits. Some states that previously carved out drug benefits are considering moving to carve-in arrangements, where the private insurers are responsible for managing integrated drug benefits.⁵⁴

Proponents tout the advantages of carve-in drug programs, including improving the detection of substance abuse and “drug seekers,” raising the quality of care through better care coordination,

and identifying drug interactions and inappropriate or duplicate prescriptions. It makes sense for the health plan responsible for managing physician visits and hospital needs to also coordinate drug therapies, because skimping on drug therapies often leads to higher medical costs.

Negotiating Drug Prices. The cost of drugs purchased for state Medicaid programs varies from one state to another. A 2004 report by the Office of Inspector General of the U.S. Department of Health and Human Services compared the amounts states paid for 28 common drugs across 42 state Medicaid programs.⁵⁵ Michigan and Texas performed the best; New York and New Jersey fared the worst. The price of Lipitor (a popular drug used to treat high cholesterol) varied from \$2.58 to \$2.89 — only about a 12 percent difference. For Depakote (a drug used to treat bipolar disorder), costs varied by more than 70 percent. State payment for generic drugs with multiple suppliers varied the most. For example, the cost of Atenolol (a popular beta blocker used to treat high blood pressure) varied by 4,073 percent between low- and high-cost states.

A 2009 Inspector General’s report compared the cost of drugs obtained for the privately-run Medicare Part D program with the cost of drugs for Medicaid. Costs of brand-name drugs under patent protection varied by less than 5 percent. For generic drugs, state Medicaid programs paid at least 10 percent more than Medicare Part D plans for three-fourths of the drugs surveyed.⁵⁶ This is in contrast to the private firms that manage Medicare Part D and private drug plans, which often pay less for

drugs than Medicaid fee-for-service programs because pharmacy benefit managers negotiate prices with manufacturers more aggressively.⁵⁷

*Empowering Consumers.*⁵⁸ In the private sector, patients are increasingly required to share in the cost of health care by paying deductibles and copayments. The evidence shows that when individuals have the proper financial incentives, they will be better consumers of health care.⁵⁹ This usually involves health plans in which a person pays some medical expenses out-of-pocket or from a personal account established for that purpose. For instance, a number of states have received federal waivers to set up cash accounts that allow disabled Medicaid recipients to manage their own health care dollars and personally control the hiring of home care

“What states pay for one popular drug varies by 4,073 percent!”

services.⁶⁰ These programs, called “Cash and Counseling,” use a defined contribution approach.⁶¹ Remarkably, patient satisfaction is almost 100 percent.⁶²

Mail-Order Pharmacies. Although drugstore chains still sell the most drugs, mail-order pharmacies are gaining ground and now account for about 17 percent of the retail drug market. Mail-order and Internet pharmacies offer the

best deals on prescription drugs for patients with chronic conditions.

*Cost-Sharing.*⁶³ For some years now, private health insurers have successfully used copayments and increased cost-sharing to reduce unnecessary medical services. In the past, a state was only allowed to charge nominal copayments of \$1 to \$3 for medical services and prescription drugs, unless it received a waiver.⁶⁴ The Deficit Reduction Act of 2005, however, allows states to charge nominal copays for all nonpreferred prescription drugs for Medicaid recipients 150 percent or more above the federal poverty level. Furthermore, states are permitted to increase copays commensurate with rises in the medical component of the consumer price index, and they may require mandatory populations to make copayments for nonpreferred prescription drugs. This principle might be applied to Medicaid by allowing enrollees to purchase a nonformulary drug if they make a higher copayment. If a physician thinks a nonformulary drug offers significant benefits, copayments could be waived.

Cost-sharing should not be imposed for those services and treatments that have been shown to reduce preventable medical costs. For example, states should provide first-dollar coverage for asthma treatments because hospitalizations for severe asthma attacks are costly, yet easily prevented.

Value-Based Benefit Design. Health plans often use formularies with one or two tiers: a low, fixed copayment for generic drugs and a higher copayment for name-brand

State Reform of Medicaid Drug Programs

drugs. There are opportunities to reward more valuable services by charging different copayments for drugs to treat different conditions.⁶⁵ For instance, a beta blocker for a diabetic is so beneficial that many experts believe there should be no cost sharing. On the other hand, Cox-2 inhibitors are very costly pain relievers for which many less expensive substitutes are available. The private drugs plans that manage Medicaid drug benefits should have the authority to experiment in order to discover which benefits hold the greatest value.

Conclusion

Medicaid's drug benefit program must be reformed to keep costs under control. Billions of dollars might be found in potential Medicaid savings, if only states will look to market-based solutions rather than government-imposed cost controls. However, numerous obstacles stand in the way of reform. The most formidable roadblocks to reform are lobbyists for trade associations, professional societies, independent pharmacies and drug suppliers that serve Medicaid beneficiaries. These stakeholders often oppose market-based reforms that benefit taxpayers but prove less profitable.

Endnotes

1. "Medicaid: A Primer, Key Information on Our Nation's Health Coverage Program for Low-Income People," Kaiser Family Foundation, Kaiser Commission on Medicaid and the Uninsured, June 2010.
2. "Waiting for Economic Recovery, Poised for Health Care Reform: A Mid-Year Update for FY 2011 — Looking Forward to FY 2012," Kaiser Commission on Medicaid and the Uninsured, Kaiser Family Foundation, January 2011. Also see Vernon K. Smith et al., "Hoping for Economic Recovery, Preparing for Health Reform: A Look at Medicaid Spending, Coverage and Policy Trends," Kaiser Commission on Medicaid and the Uninsured, Kaiser Family Foundation, September 30, 2010.
3. Medicaid and other health expenses already account for about 22 percent of state spending. See John C. Goodman et al., "Opportunities for State Medicaid Reform," National Center for Policy Analysis, Policy Report Number 288, September 28, 2006. Available at <http://www.ncpa.org/pub/st288>.
4. Vernon Smith et al., "The Continuing Medicaid Budget Challenge: State Medicaid Spending Growth and Cost Containment in Fiscal Years 2004 and 2005, Results from a 50-State Survey," Kaiser Commission on Medicaid and the Uninsured, Kaiser Family Foundation, October 2004.
5. Richard S. Foster, "Estimated Financial Effects of the 'Patient Protection and Affordable Care Act,' as Amended," Centers for Medicare and Medicaid Services, U.S. Department of Health and Human Services, April 22, 2010. Available at http://www.cms.gov/ActuarialStudies/Downloads/PPACA_2010-04-22.pdf.
6. Douglas W. Elmendorf, "Letter to House Speaker," Congressional Budget Office, March 20, 2010. Available at www.cbo.gov/ftpdocs/113xx/doc11379/AmendReconProp.pdf.
7. David Plunkert, "With Expanded Coverage for the Poor, Fears of a Big Headache," *New York Times*, April 26, 2010. Also see Richard S. Foster, "Estimated Financial Effects of the 'Patient Protection and Affordable Care Act,' as Amended."
8. Pamela Villarreal, "Federal Medicaid Funding Reform," National Center for Policy Analysis, Brief Analysis Number 566, July 31, 2006. Available at <http://www.ncpa.org/pdfs/ba566.pdf>.
9. "The Uninsured in America," BlueCross BlueShield Association, Publication W20-04-035, January 2005. Available at http://www.coverageforall.org/pdf/BC-BS_Uninsured-America.pdf.
10. Devon Herrick, "Medicaid Expansion Will Bankrupt the States," National Center for Policy Analysis, Brief Analysis

Number 729, October 25, 2010. Available at <http://www.ncpa.org/pdfs/ba729.pdf>.

11. A drug was either provided or prescribed in 64.8 percent of office visits. The average number of prescriptions written is 2.25 per patient when they receive one during the course of an office visit. David A. Woodwell and Donald K. Cherry, "National Ambulatory Medical Care Survey: 2002 Summary," National Center for Health Statistics, Advance Data from Vital and Health Statistics, Number 346, August 26, 2004.
12. Frank R. Lichtenberg, "Why Has Longevity Increased Faster in Some States than Others? The Role of Medical Innovation and other Factors," Manhattan Institute, Medical Progress Report Number 4, July 2007. Available at http://www.manhattan-institute.org/html/mpr_04.htm.
13. John C. Goodman et al., "Opportunities for State Medicaid Reform."
14. John Norton, "Lewin Group/PBMs' Medicaid Pharmacy Report Misses the Mark; Recommendations Threaten Patient Health and Access," January 20, 2011. Available at <http://ncpanet.wordpress.com/2011/01/20/lewin-grouppbms%E2%80%99-medicaid-pharmacy-report-misses-the-mark-recommendations-threaten-patient-health-and-access/>.
15. "Lewin's Medicaid Pharmacy Managed Care Report: Bought and Paid for by PBMs Threatens Patient Health, Compromises State Medicaid Programs, Reduces Patient Access to Pharmacies," National Community Pharmacists Association, January 2011. Available at http://www.ncpanet.org/pdf/leg/jan11/lewin_group_report_final.pdf.
16. Under the Affordable Care Act, drug manufacturers are required to provide rebates of at least 23.1 percent on name brand drugs. Prior to the Act reimbursements were at least 15.1 percent. The average rebate to state Medicaid programs in 2009 was 38.5 percent. Christopher Weaver, "States' Medicaid Funds Tapped For Federal Health Overhaul," *Kaiser Health News*, April 20, 2010. For a primer on Medicaid drug rebates, see Kip Piper, "Medicaid Drug Rebate: Briefing for Medicaid Health Plans of America," Wellers Dorsey, Webinar, May 25, 2010. Available at http://www.mhpa.org/_upload/SDwebinarMay2010.pdf.
17. Vernon K. Smith et al., "Hoping for Economic Recovery, Preparing for Health Reform: A Look at Medicaid Spending, Coverage and Policy Trends," Kaiser Family Foundation, Kaiser Commission on Medicaid and the Uninsured, September 30, 2010.
18. These include Alabama, Arkansas, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Kentucky, Massachusetts, Minnesota, Mississippi, Montana, New Hampshire, New Jersey, New Mexico, North and South Carolina, North and South Dakota, Oklahoma, Texas, Virginia and Wyoming. See "Managed Care State Laws and Regulations, Including Consumer and Provider Protections," National Conference of State Legislatures, Table I, September 2011. Available at <http://www.ncsl.org/issues-research/health/managed-care-state-laws.aspx>.
19. "Pharmacy-Related Changes from the 82nd Legislature," Texas Health and Human Services Commission, *RxUpdate*, Volume 21, Number 3, Summer 2011. Available at <http://www.txvendordrug.com/downloads/newsletters/2011-q3.pdf>.
20. Alain Enthoven and Kyna Fong, "Medicare: Negotiated Drug Prices May Not Lower Costs," National Center for Policy Analysis, Brief Analysis Number 575, December 18, 2006. Available at <http://www.ncpa.org/pub/ba575>.
21. Christine Piette Durrance, "The Impact of Pharmacy-Specific Any-Willing-Provider Legislation on Prescription Drug Expenditures," *Atlantic Economic Journal*, Volume 37, Number 4, August 2009, pages 409-423.
22. F. J. Hellinger, "Any-Willing-Provider and Freedom-of-Choice Laws: An Economic Assessment," *Health Affairs*, Volume 14, Number 4, 1995, pages 297-302.
23. "Improving Health Care: A Dose of Competition," Federal Trade Commission and the U.S. Department of Justice, July 2004. Available at <http://www.ftc.gov/reports/healthcare/040723healthcarerpt.pdf>.
24. Robert L. Ohsfeldt et al., "The Spread of State Any Willing Provider Laws," *HSR: Health Service Research*, Volume 35,

State Reform of Medicaid Drug Programs

Number 5, December 1998.

25. Timothy P. Millar et al., “Applying the Essential Medicines Concept to US Preferred Drug Lists,” *American Journal of Public Health*, Volume 101, Number 8, August 2011, pages 1,444-1,448.
26. Shawna Kittridge et al., “Medicaid Prescription Drugs: Purchasing and Management,” Medicaid Institute at United Hospital Fund, July 2011. Available at <http://www.uhfny.org/assets/913>.
27. Kimberly Ovsag, Sabrina Hyder and Shaker A. Mousa, “Preferred Drug Lists: Potential Impact on Healthcare Economics,” *Vascular Health Risk Management*, Volume 4, Number 2, April 2008, pages 403–413.
28. Richard A. Levy and Douglas Cocks, “Component Management Fails to Save Health Care System Costs: The Case of Restrictive Formularies (Second Edition),” National Pharmaceutical Council, 1999. Available at http://npcdev.npcnow.org/App_Themes/Public/pdf/Issues/pub_related_research/pub_component/Component%20Management%20Fails%20to%20Save%20nd%20Ed.pdf.
29. William J. Moore and Etienne E. Pracht, “Changes in the Effectiveness of State Medicaid Drug Program Cost-Containment Policies Following OBRA 1990,” *American Journal of Economics and Sociology*, Symposium on Medical Economics, January 15, 2008.
30. Stephen B. Soumerai, “Benefits and Risks of Increasing Restrictions on Access to Costly Drugs in Medicaid,” *Health Affairs*, Volume 23, Number 1, January 2004, pages 135-146.
31. Jerome Wilson, Kirsten Axelsen and Simon Tang, “Medicaid Prescription Drug Access Restrictions: Exploring the Effect on Patient Persistence with Hypertension Medications,” *American Journal of Managed Care*, Volume 11, 2005, pages SP27-SP34.
32. Haiden A. Huskamp, “Managing Psychotropic Drug Costs: Will Formularies Work?” *Health Affairs*, Volume 22, Number 5 September/October 2003, pages 84-96.
33. Joel Menges et al., “Projected Impacts of Adopting a Pharmacy Carve-In Approach Within Medicaid Capitation Programs,” Lewin Group, February 2011. Available at <http://www.lewin.com/content/publications/MHPAPaperPharmacyCarve-In.pdf>.
34. The states are Connecticut, Delaware, Illinois, Indiana, Iowa, Missouri, Nebraska, New York, Ohio, Tennessee, Texas, Utah, West Virginia and Wisconsin. See Joel Menges et al., “Projected Impacts of Adopting a Pharmacy Carve-In Approach Within Medicaid Capitation Programs.”
35. Joel Menges, Shirley Kang and Chris Park, “Potential Federal and State-by-State Savings if Medicaid Pharmacy Programs Were Optimally Managed,” Lewin Group, 2011
36. “Economic Analysis of Generic Pharmaceuticals 1998-2008, \$824 Billion in Health Care Savings,” Generic Pharmaceutical Association, May 2009. Available at <http://www.gphaonline.org/about-gpha/about-generics/case/generics-providing-savings-americans>.
37. Aidan Hollis, “Closing the FDA’s Orange Book,” *Regulation*, Winter 2001.
38. Alaric DeArment, “As Innovators Prep For Patent Cliff, Generics Prosper From Patent Losses,” *Drug Store News*, February 18, 2011. Alex Brill of the American Enterprise Institute, predicts Medicaid will waste \$289 million to \$433 million annually on drugs that go off-patent in 2011 and 2012 and become available from multiple sources. See Alex Brill, “Overspending on Multi-Source Drugs in Medicaid,” American Enterprise Institute, AEI Health Policy Studies Working Paper 2011-01, March 28, 2011. Available at: <http://www.aei.org/paper/100207>.
39. Michael Kleinrock, “The Use of Medicines in the United States: Review of 2010,” IMS Institute for Health

Informatics, April 2011.

40. Joseph P. Cook, Graeme Hunter and John A. Vernon, “Generic Utilization Rates, Real Pharmaceutical Prices, and Research and Development Expenditures,” National Bureau of Economic Research, Working Paper Number 15723, February 2010.
41. William M. Welch, “VA Offers Medicines at Bargain Prices,” *USA Today*, June 18, 2003.
42. Analysis by the National Community Pharmacists Association. See John M. Coster, “Changes in Medicaid Reimbursement: Implications for Generic Manufacturers and Pharmacies,” *U.S. Pharmacist*, Vol. 36, No. 6 (Generic Supplement), June 20, 2011, pages 12-20.
43. Frank R. Lichtenberg, “The Impact of New Drug Launches on Longevity: Evidence from Longitudinal Disease-Level Data from 52 Countries, 1982-2001,” National Bureau of Economic Research, Working Paper Number 9754, June 2003.
44. Joel Menges, Shirley Kang and Chris Park, “Potential Federal and State-by-State Savings if Medicaid Pharmacy Programs Were Optimally Managed.”
45. A recent poll found 85 percent of voters favor generic-first dispensing policies for Medicaid. Jon McHenry and Whit Ayres, “Voter Attitudes Regarding Medicaid Pharmacy Spending,” Ayres, McHenry & Associates, Inc., December 10, 2010. Available at <http://pcmanet.org/images/stories/uploads/2010/12/Medicaid-Pharmacy-Poll-Memo.pdf>.
46. Data from 2009. See Alex Brill, “Overspending on Multi-Source Drugs in Medicaid,” American Enterprise Institute, AEI Health Policy Studies Working Paper 2011-01, March 28, 2011. Available at <http://www.aei.org/paper/100207>.
47. A recent poll found about 80 percent of voters are not in favor of overcompensating drug stores beyond what private drug plans would pay for Medicaid prescriptions. The same poll found voters were not in favor of cutting reimbursement to doctors and hospitals. See Jon McHenry and Whit Ayres, “Voter Attitudes Regarding Medicaid Pharmacy Spending.”
48. Joel Menges, Shirley Kang and Chris Park, “Potential Federal and State-by-State Savings if Medicaid Pharmacy Programs Were Optimally Managed.”
49. Ibid.
50. Some states pay even higher fees to low volume or rural pharmacies. See “Medicaid Prescription Reimbursement Information by State — Quarter Ending December 2010,” Center for Medicare & Medicaid Services, U.S. Department of Health and Human Services. Available at <https://www.cms.gov/Reimbursement/downloads/4Q2010ReimbursementChart.pdf>.
51. Daniel R. Levinson, “Comparing Pharmacy Reimbursement: Medicare Part D to Medicaid,” U.S. Department of Health and Human Services, Office of Inspector General, Publication OEI-03-07-00350, February 2009.
52. Dispensing fees at long-term care pharmacies were generally twice as high as retail pharmacies. See Stuart Wright, “Medicare Part D Pharmacy Discounts for 2008,” U.S. Department of Health and Human Services, Office of the Inspector General, Memorandum Report: OEI-02-10-00120, November 17, 2010. Available at <http://oig.hhs.gov/oei/reports/oei-02-10-00120.pdf>.
53. Wes Joines, Joel Menges and Jennifer Tracey, “Programmatic Assessment of Carve-In and Carve-Out Arrangements for Medicaid Prescription Drugs,” Lewin Group, October 17, 2007.
54. Chelsey Ledue, “Report: Ohio’s Medicaid PBM carve-out isn’t working,” *Healthcare Finance News*, July 21, 2010.
55. “Variation in State Medicaid Drug Prices,” U.S. Department of Health and Human Services, Office of Inspector General, Publication OEI-05-02-00681, September 2004.

State Reform of Medicaid Drug Programs

56. Fourteen drugs were surveyed. See Daniel R. Levinson, “Comparing Pharmacy Reimbursement: Medicare Part D to Medicaid.”
57. Daniel R. Levinson, “Comparing Pharmacy Reimbursement: Medicare Part D to Medicaid.”
58. See John C. Goodman et al., “Opportunities for State Medicaid Reform.”
59. Emmett B. Keeler, “Effects of Cost Sharing on Use of Medical Services and Health,” RAND Corporation, 1992. Available at <http://www.rand.org/pubs/reprints/RP1114/index.html>. Accessed March 28, 2011.
60. Jeffrey S. Crowley, “An Overview of the Independence Plus Initiative to Promote Consumer-Direction of Services in Medicaid,” Kaiser Commission on Medicaid and the Uninsured, Henry J. Kaiser Family Foundation, Issue Paper, November 2003.
61. To facilitate the process of applying for these waivers, the Bush administration created a template waiver called Independence Plus. See Karen Tritz, “Long-Term Care: Consumer-Directed Services under Medicaid,” CRS Report for Congress, Congressional Research Service, Library of Congress, January 21, 2005.
62. James Frogue, “The Future of Medicaid: Consumer-Directed Care,” Heritage Foundation, Background Number 1618, January 10, 2003. Available at <http://www.heritage.org/research/healthcare/BG1618.cfm>.
63. For example, see Thomas M. Selden et al., “Cost Sharing in Medicaid and CHIP: How Does it Affect Out-Of-Pocket Spending?” *Health Affairs*, Volume 28, Number 4, June 2, 2009, pages w607-w619.
64. Utah received a waiver in 2002 that allowed it to increase cost sharing through enrollment fees and copayments. Oregon received a waiver to impose nominal premiums of \$6 to \$20 per month. For a discussion see Marilyn Werber Serafini, “Balancing Act,” *National Journal*, August 13, 2005.
65. Michael E. Chernew, Allison B. Rosen and A. Mark Fendrick, “Value-Based Insurance Design,” *Health Affairs*, Volume 26, Number 2, January 2, 2007, pages w195-w203.
66. Linda Gorman, “Medicaid Drug Formularies: Do They Perform as Advertised?” Health Care Policy Center, Independence Institute, Issue Paper Number 2-2002, April 2002.

About the Author

Devon Herrick is a senior fellow with the National Center for Policy Analysis. He concentrates on such health care issues as Internet-based medicine, health insurance and the uninsured, and pharmaceutical drug issues. His research interests also include managed care, patient empowerment, medical privacy and technology-related issues.

Herrick received a Doctor of Philosophy degree in political economy and a Master of Public Affairs degree from the University of Texas at Dallas. He also holds Master of Business Administration degrees from Oklahoma City University and Amber University.

The NCPA is a nonprofit, nonpartisan organization established in 1983. Its aim is to examine public policies in areas that have a significant impact on the lives of all Americans — retirement, health care, education, taxes, the economy, the environment — and to propose innovative, market-driven solutions. The NCPA seeks to unleash the power of ideas for positive change by identifying, encouraging and aggressively marketing the best scholarly research.

Health Care Policy.

The NCPA is probably best known for developing the concept of Health Savings Accounts (HSAs), previously known as Medical Savings Accounts (MSAs). NCPA President John C. Goodman is widely acknowledged (*Wall Street Journal*, WebMD and the *National Journal*) as the “Father of HSAs.” NCPA research, public education and briefings for members of Congress and the White House staff helped lead Congress to approve a pilot MSA program for small businesses and the self-employed in 1996 and to vote in 1997 to allow Medicare beneficiaries to have MSAs. In 2003, as part of Medicare reform, Congress and the President made HSAs available to all nonseniors, potentially revolutionizing the entire health care industry. HSAs now are potentially available to 250 million nonelderly Americans.

The NCPA outlined the concept of using federal tax credits to encourage private health insurance and helped formulate bipartisan proposals in both the Senate and the House. The NCPA and BlueCross BlueShield of Texas developed a plan to use money that federal, state and local governments now spend on indigent health care to help the poor purchase health insurance. The SPN Medicaid Exchange, an initiative of the NCPA for the State Policy Network, is identifying and sharing the best ideas for health care reform with researchers and policymakers in every state.

**NCPA President
John C. Goodman is called
the “Father of HSAs” by
The Wall Street Journal, WebMD
and the *National Journal*.**

Taxes & Economic Growth.

The NCPA helped shape the pro-growth approach to tax policy during the 1990s. A package of tax cuts designed by the NCPA and the U.S. Chamber of Commerce in 1991 became the core of the Contract with America in 1994. Three of the five proposals (capital gains tax cut, Roth IRA and eliminating the Social Security earnings penalty) became law. A fourth proposal — rolling back the tax on Social Security benefits — passed the House of Representatives in summer 2002. The NCPA’s proposal for an across-the-board tax cut became the centerpiece of President Bush’s tax cut proposals.

NCPA research demonstrates the benefits of shifting the tax burden on work and productive investment to consumption. An NCPA study by Boston University economist Laurence Kotlikoff analyzed three versions of a consumption tax: a flat tax, a value-added tax and a national sales tax. Based on this work, Dr. Goodman wrote a full-page editorial for *Forbes* (“A Kinder, Gentler Flat Tax”) advocating a version of the flat tax that is both progressive and fair.

A major NCPA study, “Wealth, Inheritance and the Estate Tax,” completely undermines the claim by proponents of the estate tax that it prevents the concentration of wealth in the hands of financial dynasties. Actually, the contribution of inheritances to the distribution of wealth in the United States is surprisingly small. Senate Majority Leader Bill Frist (R-TN) and Senator Jon Kyl (R-AZ) distributed a letter to their colleagues about the study. In his letter, Sen. Frist said, “I hope this report will offer you a fresh perspective on the merits of this issue. Now is the time for us to do something about the death tax.”

Retirement Reform.

With a grant from the NCPA, economists at Texas A&M University developed a model to evaluate the future of Social Security and Medicare, working under the direction of Thomas R. Saving, who for years was one of two private-sector trustees of Social Security and Medicare.

The NCPA study, “Ten Steps to Baby Boomer Retirement,” shows that as 77 million baby boomers begin to retire, the nation’s institutions are totally unprepared. Promises made under Social Security, Medicare and Medicaid are inadequately funded. State and local institutions are not doing better — millions of government workers are discovering that their pensions are under-funded and local governments are retrenching on post-retirement health care promises.

Pension Reform.

Pension reforms signed into law include ideas to improve 401(k)s developed and proposed by the NCPA and the Brookings Institution. Among the NCPA/Brookings 401(k) reforms are automatic enrollment of employees into companies’ 401(k) plans, automatic contribution rate increases so that workers’ contributions grow with their wages, and better default investment options for workers who do not make an investment choice.

The NCPA's online Social Security calculator allows visitors to discover their expected taxes and benefits and how much they would have accumulated had their taxes been invested privately.

Environment & Energy.

The NCPA's E-Team is one of the largest collections of energy and environmental policy experts and scientists who believe that sound science, economic prosperity and protecting the environment are compatible. The team seeks to correct misinformation and promote sensible solutions to energy and environment problems. A pathbreaking 2001 NCPA study showed that the costs of the Kyoto agreement to reduce carbon emissions in developed countries would far exceed any benefits.

Educating the next generation.

The NCPA's Debate Central is the most comprehensive online site for free information for 400,000 U.S. high school debaters. In 2006, the site drew more than one million hits per month. Debate Central received the prestigious Templeton Freedom Prize for Student Outreach.

Promoting Ideas.


NCPA studies, ideas and experts are quoted frequently in news stories nationwide. Columns written by NCPA scholars appear regularly in national publications such as the *Wall Street Journal*, the *Washington Times*, *USA Today* and many other major-market daily newspapers, as well as on radio talk shows, on television public affairs programs, and in public policy newsletters. According to media figures from Burrelle's, more than 900,000 people daily read or hear about NCPA ideas and activities somewhere in the United States.

What Others Say About the NCPA



"The NCPA generates more analysis per dollar than any think tank in the country. It does an amazingly good job of going out and finding the right things and talking about them in intelligent ways."

Newt Gingrich, former Speaker of the U.S. House of Representatives



"We know what works. It's what the NCPA talks about: limited government, economic freedom; things like Health Savings Accounts. These things work, allowing people choices. We've seen how this created America."

John Stossel,
former co-anchor ABC-TV's 20/20



"I don't know of any organization in America that produces better ideas with less money than the NCPA."

Phil Gramm,
former U.S. Senator



"Thank you . . . for advocating such radical causes as balanced budgets, limited government and tax reform, and to be able to try and bring power back to the people."

Tommy Thompson,
former Secretary of Health and Human Services